semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 0.0-5.0,  Primary Hyperoxaluria Primary Hyperoxaluria Type 1 (PH1) Has confirmation of primary hyperoxaluria type 1 (PH1) Meets urinary oxalate excretion requirements If taking Vitamin B6 (pyridoxine), must have been on stable regimen for at least 90 days  Abnormal serum creatinine levels at screening for infants who are less than 1 year old Does not have relatively preserved kidney function Clinical evidence of systemic oxalosis History of kidney or liver transplant
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 30.0-60.0,  PreDiabetes Fasting Plasma Glucose between 100 mg/dL (5.6 mmol/L) to 125 mg/dL (6.9 mmol/L) 2 Oral Glucose Tolerance Test 140 mg/dL (7.8 mmol/L) to 199 mg/dL (11.0 mmol/L) 3 A1C 5.7-6.4% (39-47 mmol/mol). 4 Body Mass Index >25 kg/m2 or >23 kg/m2 5 Adults who have one or more of the following risk factors First-degree relative with diabetes High-risk race/ethnicity History of CVD 6 Blood Pressure <140/90 mmHg without therapy for hypertension 7 HDL cholesterol level <0.35 mg/dL (0.90 mmol/L) and/or a triglyceride level >0.250 mg/dL (2.82 mmol/L)  Pregnant women or lactic period 2 Patients with some other chronic degenerative disease like diabetes mellitus 2 with pharmacologic treatment. 3 Hypertension 4 Cancer, 5 Hyperthyroidism 6 Hypothyroidism 7 Immunologic disease 8 Kidney disease 9 Hepatic disease 10 Cardiovascular disease 11
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetes Mellitus Physical Activity Dietetic Rules Therapeutic Education Patient with type 2 diabetes defined by (HAS 2013) a blood glucose level above 1.26 g / l (7.0 mmol / l) after an 8-hour fast and checked twice or the presence of symptoms of diabetes (polyuria, polydipsia, weight loss) associated with blood glucose (on venous plasma) greater than or equal to 2 g / l (11.1 mmol / l) or blood glucose (on venous plasma) greater than or equal to 2 g / l (11.1 mmol / l) 2 hours after an oral load of 75 g of glucose (criteria proposed by the World Health Organization). 2. Patient with HbA1c at inclusion> 7 and <12% (on an HbA1c dose less than 6 months old at the prescreening) 3. Patient with a BMI ≥ 25 and a weight ≤ 125 kg 4. Patient with appropriate treatment 5. Age ≥ 18 years 6. Available to go on treatment in 6 weeks after 7. Available for a 12-month follow-up 8. Affiliated to the social security or beneficiary of such a scheme  Diabetes type 1 or secondary 2. Patient with GFR (glomerular filtration rate) <50 ml / min (MDRD formulation) for at least 1 year. 3. Unstable diabetes defined by the knowledge of the questioning of a change in HbA1c of +/ in the last 6 months. 4. With known serious comorbidity and / or limited life expectancy (<5 years), or with advanced macrovascular complications: in particular cardiovascular (acute coronary diseases and / or stroke in the last 6 months) and renal 5. Severe psychiatric pathology or psychosis 6. Pregnant woman, parturient or breastfeeding 7. Contraindication to hydrotherapy 8. Patient with a contraindication to moderate physical activity or cycling (acute coronary artery disease less than 2 years old, musculoskeletal problem of the spine or lower limbs incompatible with cycling). 9. No previous spa treatment for "Digestive disorders and metabolic diseases" in the current the spa year. 10. Person deprived of liberty or legal protection measure 11. Subject participating to an other clinical study interventional
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Angina, Stable No contraindication for pulmonary physiotherapy Anjina patients who are clinically stable have no other disease that may affect respiratory function Individuals who have the good cooperation  Patients under the age of 18 Pregnancy Active infection Patients with known malignancies patients without consent known arrhythmia, dilated or hypertrophic cardiomyopathy, heart failure (EF <40%)
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 30.0-999.0,  Heart Failure Age ≥ 30 years Symptoms of severe dyspnea (III-IV) without evidence of a non-cardiac or ischemic explanation for dyspnea EF of > or = 50% determined on most recent imaging study within the preceding 5 years, with no change in clinical status suggesting potential for deterioration in systolic function One of the following Previous hospitalization for HF with radiographic evidence (pulmonary venous hypertension, vascular congestion, interstitial edema, pleural effusion) of pulmonary congestion or Catheterization documented elevated filling pressures at rest (PCWP ≥15 or LVEDP ≥18) or with exercise (PCWP ≥25) or Elevated NT-proBNP (>400 pg/ml) or BNP(>200 pg/ml) or Echo evidence of diastolic dysfunction/elevated filling pressures manifest by medial E/e' ratio≥15 and/or left atrial enlargement and chronic treatment with a diuretic for signs or symptoms of heart failure Heart failure is primary factor limiting activity as indicated by answering # 2 to the following question: My ability to be active is most limited by Joint, foot, leg, hip or back pain  Recent (< 1 month) hospitalization for heart failure Left or right ventricular dilatation noted on cardiac imaging study prior to enrollment (either echocardiography or MRI) Any hemoglobin (Hgb) < 8.0 g/dl within 30 days prior to randomization Any GFR < 20 ml/min/1.73 m2 within 30 days prior to randomization Significant alternative cause of dyspnea such as severe chronic obstructive pulmonary disease that is a primary contributor to symptoms in the opinion of the investigator Ischemia thought to contribute to dyspnea in the opinion of the investigator Acute coronary syndrome within 3 months defined by electrocardiographic (ECG) changes and biomarkers of myocardial necrosis (e.g., troponin) in an appropriate clinical setting (chest discomfort or anginal equivalent) PCI, coronary artery bypass grafting, or new biventricular pacing within past 3 months Obstructive hypertrophic cardiomyopathy Known infiltrative cardiomyopathy (amyloid)
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 20.0-55.0,  Diabetes Mellitus, Type 1 Diabetic Cardiomyopathies Autonomic Neuropathy, Diabetic type 1 diabetes mellitus  hypertension coronary artery disease heart valve disease ventricular dysfunction radiotherapy or chemotherapy alcoholism limited acoustic window
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  Chronic Obstructive Pulmonary Disease Age 21 years and above 2. Known diagnosis of COPD based on history AND spirometry demonstrating post bronchodilator FEV1/FVC ratio <0.7 3. Currently admitted inpatient for an acute COPD exacerbation as the primary diagnosis 4. Fit to participate in exercise therapy as determined by both physician and physiotherapist 5. Has the mental capacity to follow instructions 6. Experience shortness of breath on exertion 7. Have decreased ability to carry out activities due to shortness of breath 8. Willing to participate in the exercise program  Uncontrolled/ unstable medical conditions such as severe chronic heart failure that make exercise unsafe 2. Pulmonary disorder other than COPD 3. Physical conditions that preclude the ability to participate in exercise or may impair exercise performance
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 55.0-75.0,  Hypertension Aged 55 to 75 years old, male or female Having a history of hypertension for more than 2 years but can maintain SBP ≤ 140 mmHg and BDP ≤ 90 mmHg with medication； ≤ MMSE < 26, or 14 ≤ MoCA < 26, CDR < 0.5. Bseides, the chief complaint must happen after having hypertension； Meet TCM Syndrome Differentiation Standard：according to the Guidelines for the Clinical Research of Chinese Medicine New Drugs ( published by China Medical Science Press ) ：Overabundant liver-fire type：dizziness and headache, both face and eyes are red, dry mouth and bitter taste in mouth, red tongue with yellowish coating, wire and frequent pulse. Yin deficiency and yang hyperactivity type: dizziness and headache, Tinnitus and forgetfulness, sphoria with feverish sensation in chest & palms & soles, palpitation and insomnia, red tongue & thin white or less coating, wiry weak and numbered pulse； CTMRI hint: leukoaraiosis and no sign of Cerebral infarction； Patients or the guardian hold the right opinions over the research and are willing to obey researcher's orders； Having a certain degree of education (being able to read simple newspapers in the past)； Patients agree to sign informed consent。  Secondary hypertension； Taking certain kinds of antihypertensive drugs which may damage brain cognitive function； Diagnosed as depression or other mental disorders according to DSM-IV； Diagnosed as vascular dementia according to diagnostic CDR ≥ 0.5; alzheimer disease or dementia caused by some other reasons (including mixed dementia according to diagnostic for VCI); cognitive impairment due to head injury。 Suffering from certain kinds of diseases which may interfere the assessment of cognitive function, including those who are diagnosed as alcoholics and drugs or psychotropic medicine abusers during the last 5 years according to DSM-IV； Accompanied with severe neurological function disorder； Asthma, chronic severe primary cardiovascular disease, liver lesion, hematological lesions, lung diseases, diabetes or other severe diseases may influence the patients' survival such as cancer or AIDS； Other: Such as poor compliance, or can not attend the follow-up visit in time for some reasons； Taking the same kind of medicine during the last 30 days which may influence the trial； Is participating in another clinical study；
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Gut Microbiome Cholesterol, LDL Cholesterol, HDL Healthy English and Spanish speaking males and females with elevated circulating cholesterol levels (LDL-c ≥ 120 mg/dL) Individuals with LDL-c > 190 mg/dL will be permitted to participate but must provide a letter from their doctor stating that they are comfortable with their participation in the study  recent weight fluctuations (> 5 lb in past 3 months), following specialized or restrictive diets (e.g. carbohydrate restriction, veganism) use of supplements (antioxidants, fiber, botanicals) allergies to dairy, egg, wheat, corn or gluten use of antibiotics in the past 2-3 months use of lipid lowering medications regular physical activity ≥ 30 min/d for ≥ 5 days/wk history of thyroid disorders, diabetes, heart disease, cancer, hepatitis, inflammatory conditions and/or gastrointestinal disorders which may impact gut function and metabolism anyone with a fear of needles or blood draws If female, women may not be pregnant or lactating during the study Unwillingness to comply with study protocols will also result in from the study
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 0.0-25.0,  Diabetes Mellitus, Type 1 Monogenic Diabetes Neonatal Diabetes Maturity-onset Diabetes in the Young (MODY) Wolfram Syndrome Wolcott-Rallison Syndrome Mitochondrial Diabetes Diagnosis of diabetes under the age of 25 as either type 1 or undetermined type  Existing T1D autoantibody testing with a positive result
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 30.0-75.0,  Cardiovascular Diseases Heart Failure Coronary Artery Disease Mesenchymal Stem Cell Transplantation Regenerative Medicine Patients with a diagnosis of coronary disease, performed by coronary angiography, requiring conventional coronary revascularization surgery History of myocardial infarction; evidence of akinesia or regional dyskinesia more than 1 week old Ejection fraction less than 40% Age between 30 and 75 years Negative serology for HIV, hepatitis B virus (HBV), and hepatitis C virus HCV Negative pregnancy test for women of childbearing age Patients who sign the informed consent complying with all of the provisions of current regulations in Colombia  History of myocardial infarction with ST-segment elevation within 2 weeks prior to surgery History of myocardial infarction without ST-segment elevation within the previous week (the decision to these patients within the first week after suffering a non-ST elevation infarction is at the discretion of the research team) Previous history of tachycardia or ventricular fibrillation History of active neoplasia or previous chemotherapy treatment Severe or uncontrolled concomitant disease (i.e., poorly controlled chronic kidney or liver failure) Patients who, due to their place of residence, mental health or social situation, have difficulty meeting the conditions of the protocol Women who are pregnant or breast-feeding Patients or legal representatives withdrawing informed consent at any time during the study Previous history of heart transplant Patients with functional organ impairment: liver function: total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase greater than 2 times the upper reference limit; kidney function: serum creatinine > 1.5 mg/dl or creatinine clearance < 60 ml/min
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 45.0-80.0,  Chronic Obstructive Pulmonary Disease Veterans from all sex/gender, race, and ethnicity will be recruited All subjects will undergo post-bronchodilator spirometry and be clinically stable All subjects must have documented FEV1/FVC ratio of <0.7, and between 30% to 80% FEV1% predicted If subjects have non-qualifying spirometry, they will not be screened further Subjects with qualifying spirometry will be screened further Potential subjects must have a BMI of less than 35 kg/m2 and must be free from co-morbidities that may affect walking patterns e.g., peripheral arterial disease, diabetes, low back pain  Confounding effects such as neurological, musculoskeletal, or metabolic disease Subjects taking medications that alter mood or metabolic demand will be excluded All potential subjects must be cleared for participation by a physician after undergoing a cardiopulmonary exercise test
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Cardiovascular Disease Men or women between 18 and 65 years of age Levels of LDL-cholesterol between 100 and 190 mg/dL Accept freely to participate in the study and sign the informed consent document  Be pregnant Have planned to carry out a dietary intervention or exercise practice with the aim of losing weight in the coming weeks Suffer from a serious illness Have diabetes Having a cerebrovascular disease Be taking products or drugs to control cholesterol levels or with antioxidant activity